The U.S. brain tumor market is anticipated to reach USD 4.35 billion by 2034, growing at a CAGR of 9.87% from 2025 to 2034. The market growth is primarily driven by the increasing prevalence of brain cancer and rising number of brain tumor diagnoses in the U.S. For instance, according to the National Brain Tumor Society report, an estimated one million Americans are currently living with a primary brain tumor, highlighting a substantial patient population in need of effective treatment options. Among these tumors, approximately 72% were classified as benign, while 28% were malignant in 2023, indicating a diverse range of treatment needs and approaches. Furthermore, according to the same source, non-malignant meningiomas represent the most prevalent type of primary non-malignant brain tumors, comprising approximately 39.7% of all brain tumors and 55.4% of all non-malignant tumors.
Increasing funding and investments from both public and private sectors are also driving market expansion and further fueling market growth. Furthermore, continued innovation in treatment options, including targeted therapies, immunotherapies, and advancements in surgical techniques is playing a crucial role in market expansion. Breakthroughs in precision medicine allow for more personalized treatment plans, which enhance patient outcomes and attract investment.
The market growth stage is high, and the pace of the market growth is accelerating. The U.S. brain tumor market is characterized by growth owing to the rising prevalence of brain tumors, along with better diagnostic tools, innovations in treatment modalities, such as targeted therapies, substantial funding for brain tumor research from government, non-profits, and private sectors, and availability of a wide range of treatment options, including surgery, radiation therapy, and chemotherapy, among others.
This product will be delivered within 1-3 business days.
Increasing funding and investments from both public and private sectors are also driving market expansion and further fueling market growth. Furthermore, continued innovation in treatment options, including targeted therapies, immunotherapies, and advancements in surgical techniques is playing a crucial role in market expansion. Breakthroughs in precision medicine allow for more personalized treatment plans, which enhance patient outcomes and attract investment.
The market growth stage is high, and the pace of the market growth is accelerating. The U.S. brain tumor market is characterized by growth owing to the rising prevalence of brain tumors, along with better diagnostic tools, innovations in treatment modalities, such as targeted therapies, substantial funding for brain tumor research from government, non-profits, and private sectors, and availability of a wide range of treatment options, including surgery, radiation therapy, and chemotherapy, among others.
U.S. Brain Tumor Market Report Highlights
- Based on tumor type, the malignant segment accounted for the largest revenue share in 2024 driven by the rising prevalence of brain cancer and increasing incidence of glioblastoma and high-grade malignant brain tumors
- Malignant brain tumors, including glioblastomas, often require aggressive treatment approaches, which typically involve a combination of surgery, chemotherapy, and radiation therapy
- Based on treatment type, the surgery segment accounted for the largest market share in 2024 due to several compelling factors. Firstly, surgical intervention remains the primary approach for managing many types of brain tumors, particularly malignant tumors such as glioblastomas. Surgical procedures, including craniotomy and tumor resection, aim to remove as much of the tumor as possible, which can relieve pressure on the brain, alleviate symptoms, and improve overall patient outcomes
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This Report Addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Brain Tumor Market Variables, Trends & Scope
Chapter 4. U.S. Brain Tumor Market: Tumor Type Estimates & Trend Analysis
Chapter 5. U.S. Brain Tumor Market: Treatment Type Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- GT Medical Technologies, Inc.
- Novocure
- ZAP Surgical Systems, Inc.
- Aesculap, Inc. - a B. Braun company
- Accuray Incorporated
- Carthera
- Alpheus Medical Inc.
- Alpha Tau Medical Ltd
- Elekta
- IMRIS Inc.
- Medtronic
- Monteris
- Openwater
- Acoustic MedSystems, Inc.
- NaviFUS Corp
- Insightec
- Varian Medical Systems, Inc. (Siemens Healthineers)
- RefleXion
- MagnetTx Oncology Solutions Ltd.
- NICO Corporation (Stryker)
- Terumo Interventional Systems
- Boston Scientific Corporation
- Koninklijke Philips N.V.
- IBA Worldwide
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | March 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 1.7 Billion |
| Forecasted Market Value ( USD | $ 4.35 Billion |
| Compound Annual Growth Rate | 9.8% |
| Regions Covered | United States |
| No. of Companies Mentioned | 24 |
